Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F011 - Advanced Management Strategies for Hidradentitis Supprativa

Friday, February 16; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Formulate treatment plans that appropriately integrate the surgical, laser, and medical management of hidradenitis suppurativa
  • Predict treatment responses to various medical treatments and counsel patients appropriately.
  • Surgically manage hidradenitis suppurativa in the outpatient setting


This forum is will be focused on the advanced management of hidradenitis suppurativa. Subjects covered will include medical management, office-based surgery for dermatologists, and lasers with the intent to help providers grow more comfortable with each of these modalities. Cases will be reviewed with the goal of helping practitioners select and combine these strategies to optimize the management of this complex patient population.


  • Hamzavi, Iltefat H., MD: AbbVie – A(NC); Bayer – I(Grants/Research Funding); Clinuvel – I(Fees); Eli Lilly and Company – I(Grants/Research Funding); Estee Lauder – I(Fees); Ferndale Laboratories, Inc. – I(Fees); Galderma Laboratories, L.P. – I(Fees); Global Vitiligo Foundation – B(NC); Hidradenitis Suppurativa Foundation – B(NC); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – I(Grants/Research Funding); Lenicura – I(EQ); Pfizer Inc. – I(Fees);
  • Hazen, Paul Gregory, MD: AbbVie – A(H), SP(H);
  • Jemec, Gregor B.E., MD: AbbVie – A(H), I(Grants/Research Funding); Astion Pharma – C(H); Desitin Arzneimittel GmbH – Speaker/Faculty Education(NC); InflaRx GmbH – A(H), C(H), I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding); LEO Pharma, US – I(Grants/Research Funding); Michelson Diagnostics Ltd. – I(NC); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); UCB – A(H);
  • Naik, Haley, MD: AbbVie – I(Grants/Research Funding);
  • Sayed, Christopher John, MD: AbbVie – A(Fees), I(Fees), SP(Fees); GlaxoSmithKline – I(Fees); InflaRx – I(Grants/Research Funding); Novartis – I(Fees), SP(NC); Tioga Pharmaceuticals, Inc. – I(Fees);
Friday, February 16
9:00 AM
Dr. Jemec / Non-immunomodulatory Medical Management
9:20 AM
Dr. Naik / Medical Management with Immunomodulators
9:40 AM
Dr. Jemec and Dr. Naik / Q&A Panel
9:50 AM
Dr. Sayed / Office-based surgery for HS
10:10 AM
Dr. Hamzavi / Lasers and Light
10:30 AM
Dr. Hazen / Multimodal Management of Challenging Cases
10:50 AM
Dr. Sayed, Dr. Hazen, and Dr. Hamzavi / Q&A Panel
Event Details
  • Date
    Friday, February 16
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 29D
  • CME Credits
  • Type
  • Christopher John Sayed, MD, FAAD
  • Gregor B.E. Jemec, MD
  • Haley Naik, MD, FAAD
  • Iltefat H. Hamzavi, MD, FAAD
  • Paul Gregory Hazen, MD, FAAD